← FDA ENFORCEMENT
D-0492-2024Class II

Aurobindo Pharma USA Inc.

Recalling firm
Aurobindo Pharma USA Inc.
Product type
Drug
Status
Ongoing
Report date
2024-05-15
Distribution
Nationwide in the USA
Firm state
NJ
Product quantity
6909 bottles
Initiated by
Voluntary: Firm initiated
Reason for recall

Discoloration: Dotted and yellow spots on tablets

Product description

Clorazepate Dipotassium Tablets, USP, 7.5 mg, a) 100 tablets per bottle, NDC 13107-283-01, b) 500 tablets per bottle, NDC 13107-283-05, Rx Only, Distributed by Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India.

Code / lot info

Lot #s: a) CZB124001B, CZB124002B, CZB124003B, Exp. 12/31/2025; b) CZB124001A, CZB124003A, Exp. 12/31/2025.

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.